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Abstract 
Although it is clear that the immune system is an important disease driver in multiple sclerosis 
(MS), it is presently unknown what initiates the process. Infections have been mentioned as 
potential triggers, which is specifically dealt with in other articles of this volume. Here, I give 
an overview of two fluid biomarkers that reflect key elements of the MS process: microglial 
activation (cerebrospinal fluid [CSF] sTREM2) and axonal injury (CSF and serum/plasma 
neurofilament light). I review recent data on how these markers are altered in MS, how they 
change in relation to disease progression and treatment and, finally, how they can be used as 
tools in MS research.   
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Introduction 
Multiple sclerosis (MS) is the major autoimmune disease of the brain and one of the most 
common causes of adult onset neurological disability. While the cause(s) of MS remains 
unknown, this disease is thought to be attributable to an autoimmune attack on myelin and 
oligodendrocytes by cells of the immune system that have entered the central nervous system 
(CNS). Results from genome-wide association studies, as well as the effectiveness of 
treatment strategies that directly target the activation or trafficking of T-cells and B-cells into 
the CNS, lend strong support for such a hypothesis (1). The concept that different infections 
may trigger such an immune reaction is explored in detail in other articles of this special 
volume. Here, I detail recent advances in research on biomarkers to assess microglial 
activation and axonal injury during MS onset, progression and remission, as well as in 
response to treatment.  
 
Microglial activation in MS 
Microglia are the innate immunity cells of the brain. They play important roles in normal 
brain development, as well as in adult brain plasticity and synaptic homeostasis, and may also 
respond to a wide range of CNS infections. The role of microglia in MS pathogenesis has 
been debated but some data suggest that microglial activation may precede T-cell infiltration 
and demyelination in MS lesions and aggravate axonal injury (2). 
 
Fluid biomarkers for microglial activation 
CSF concentrations of several proteins have been suggested to reflect microglial activation in 
the brain, but most of these are also expressed by astrocytes and it has been difficult to tease 
microglial and astrocytic activation apart using biomarkers. (Both processes most often occur 
in parallel, so it might not matter much from a practical point of view.) Nevertheless, one 
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cerebrospinal fluid (CSF) protein has become established as a biomarker selective for 
microglial activation: the secreted form of the triggering receptor expressed on myeloid cells 
2 (sTREM2). TREM2 is a cell surface receptor predominantly expressed on myeloid cells, for 
example, monocyte-derived dendritic cells, macrophages, mast cells, osteoclasts, and 
microglia, but importantly not astrocytes (3).  
 
In 2008, Piccio et al. first identified sTREM2 in CSF and developed an enzyme-linked 
immunosorbent assay (ELISA) with which they measured increased concentrations of 
sTREM2 in CSF samples from patients with MS, particularly so in active disease (4). 
Recently, researchers from Gothenburg confirmed this result and could also show that 
treatment with natalizumab or mitoxantrone normalised CSF sTREM2 concentrations (5).  
 
Taken together, CSF sTREM2 seems to be a dynamic biomarker for microglial activation in 
MS. Plasma or serum concentrations of this protein are influenced by release of sTREM2 
from extracerebral cell types, wherefore there is little hope for a reliable blood test.  
 
Axonal injury in MS 
Axonal injury is a prominent feature of MS responsible for both acute symptoms and long-
term disability. Structural components in axons may even be primary targets of the immune 
response in MS, as there have been reports on increased prevalence of auto-antibodies against 
neurofilaments in MS patients. 
 
Fluid biomarkers for axonal injury 
Neurofilaments are 10-nanometer filaments in the axoplasm of neurons, where they give 
tensile strength to dendrites and axons. They are composed of three major proteins with 
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molecular masses of 200, 150 and 68 kilodaltons (kD), respectively. As the name implies, 
neurofilament light (NfL) is the lightest of the three components.  
 
During the 1980s, Swedish researchers led by Professor Lars Rosengren purified 
neurofilaments from bovine brain and developed the first generation of polyclonal rabbit 
antisera specific against the individual neurofilaments (6). The most promising combination 
of these was developed into the first ELISA for NfL (7). Rosengren and colleagues showed 
that CSF NfL concentration was increased in amyotrophic lateral sclerosis (ALS), particularly 
so in patients with pyramidal tract involvement, and that increased concentrations also 
characterized Alzheimer’s disease (AD), vascular dementia and normal pressure 
hydrocephalus, but with lower magnitude of the rise compared with that seen in ALS (7). The 
authors concluded that CSF NfL was a promising biomarker for axonal injury in general; a 
conclusion that has later been confirmed in studies examining both acute and chronic CNS 
disorders (6).  
 
Monoclonal antibodies against NfL were developed and a new NfL ELISA that did not 
depend on exhaustible antisera was established (8). Given the high expression of NfL in large 
caliber myelinated axons, studies on multiple sclerosis (MS) followed. Researchers found that 
CSF NfL is increased in both relapsing-remitting and primary progressive MS, that CSF NfL 
concentration indicates ongoing axonal injury and reflects the intensity of the process, that 
CSF NfL concentration normalises within 6-12 months in MS patients following initiation of 
effective treatment and that CSF NfL thus is a promising biomarker for disease intensity and 
progression, as well as for treatment response (9).  
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NfL is detectable in serum and plasma and over the years researchers have tried to develop a 
reliable blood test. The two main obstacles have been (i) the low concentration of the protein 
in blood and (ii) the existence of heterophilic antibodies that interfere in the measurement in 
some people. Recently, the standard ELISA for CSF NfL was transferred onto the Single 
molecule array (Simoa) platform, which, together with appropriate blocking of heterophilic 
antibodies, allows for the ultrasensitive measurement of this protein in the blood (10, 11). 
Serum and plasma (there is no difference between these two matrices) NfL concentration 
measured by Simoa correlate strongly with CSF NF-L (10, 11). They also correlate with 
magnetic resonance diffusion tensor imaging parameters indicative of axonal injury in 
traumatic brain injury patients (12). Limited white matter axonal injury evoked by catheter 
insertion in MS patients who participated in a trial of a drug that was administered 
intrathecally also resulted in transient increases of serum NfL following catheter insertion, 
supporting that serum NfL is a sensitive biomarker for white matter axonal injury. This result 
is further corroborated by recent data on amateur boxers where a correlation of serum NfL 
with the number of head blows was established (13). MS patients show increased 
concentrations of serum NfL in a disease activity-dependent manner and serum concentrations 
normalise in response to disease-modifying therapy, according to two presentations at 
ECTRIMS 2016 (14, 15).  
 
Taken together, the results suggest that serum and plasma NfL may be a convenient tool to 
detect and monitor white matter axonal damage in different phases of MS longitudinally, as 
well as to follow and optimise treatment.  
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Concluding remarks 
CSF sTREM2 and CSF and serum/plasma NfL are not directly related to the pathogenesis of 
MS but represent novel tools with which important elements of the MS disease process can be 
monitored in vivo. sTREM2, a biomarker for microglial activation, necessitates CSF 
sampling, whilst NfL, a white matter axonal injury marker, can be measured in CSF or 
serum/plasma with highly correlated results. CSF sTREM2 is currently a research tool, whilst 
CSF NfL is used clinically. Serum NfL would be a very useful tool in MS clinics, not the least 
to monitor treatment, and intense efforts are currently ongoing to refine this test into an in 
vitro diagnostic product.  
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